Maintenance of response and predictive factors of 1‐year <scp>GalcanezumAb</scp> treatment in real‐life migraine patients in <scp>Italy</scp>: The multicenter prospective cohort <scp>GARLIT</scp> study

Abstract

Galcanezumab was effective and well-tolerated in the 1-year term, with most patients presenting MMD ≥50% RR for at least 9 months. Triptan response, lower BMI, and MMD ≥50% RR in the first month emerged as predictive factors for a persistent response.